Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas

被引:16
作者
Terada, K
Tamiya, T
Daido, S
Kambara, H
Tanaka, H
Ono, Y
Matsumoto, K
Ito, S
Ouchida, M
Ohmoto, T
Shimizu, K
机构
[1] Okayama Univ, Dept Mol Genet, Grad Sch Med & Dent, Okayama 7008558, Japan
[2] Okayama Univ, Dept Neurol Surg, Grad Sch Med & Dent, Okayama 7008558, Japan
关键词
allelic loss; brain tumor; DMBT1; NEURL; prognosis; PTEN;
D O I
10.1023/A:1016017711033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We thoroughly examined loss of heterozygosity (LOH) around three candidate tumor suppressor genes on chromosome 10q to determine whether LOH of each tumor suppressor gene is associated with the previously defined clinical prognostic indices. We also examined whether LOH can help predict prognostic variables in astrocytomas. We selected samples from 40 astrocytomas (grades 2-4), performed Ki-67 immunostaining, and counted positive cells. Using DNA from aliquots of tumor blocks and leukocytes, we investigated LOH around the PTEN, NEURL, and DMBT1 genes (10q23.3-26.1) with the silver staining procedure. We then statistically evaluated the relationship among histological features, regional LOH on chromosome 10q, and survival. The mean survival period for patients with LOH around PTEN was 7.2 months after surgery, while that for patients without LOH around PTEN was 21.4 months. Thus, LOH around PTEN was closely associated with a reduced overall survival (p = 0.0020) but LOH at NEURL or DMBT1 was not (p > 0.05). The combined features of an increase in histological grading and Ki-67-positive cells and the presence of LOH around PTEN significantly correlated with poor prognosis. These factors may be useful predictors of survival, and LOH analysis of tumor suppressor genes on chromosome 10q can contribute greatly to the treatment of patients with astrocytoma.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 57 条
[1]  
Albarosa R, 1996, AM J HUM GENET, V58, P1260
[2]   Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas [J].
Balesaria, S ;
Brock, C ;
Bower, M ;
Clark, J ;
Nicholson, SK ;
Lewis, P ;
de Sanctis, S ;
Evans, H ;
Peterson, D ;
Mendoza, N ;
Glaser, MG ;
Newlands, ES ;
Fisher, RA .
BRITISH JOURNAL OF CANCER, 1999, 81 (08) :1371-1377
[3]  
Barker FG, 1996, CANCER, V77, P1161, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1161::AID-CNCR24>3.0.CO
[4]  
2-Z
[5]   FAST AND SENSITIVE SILVER STAINING OF DNA IN POLYACRYLAMIDE GELS [J].
BASSAM, BJ ;
CAETANOANOLLES, G ;
GRESSHOFF, PM .
ANALYTICAL BIOCHEMISTRY, 1991, 196 (01) :80-83
[6]   CYTOGENETICS OF HUMAN BRAIN-TUMORS [J].
BIGNER, SH ;
MARK, J ;
BIGNER, DD .
CANCER GENETICS AND CYTOGENETICS, 1990, 47 (02) :141-154
[7]  
BRUNER JM, 1994, SEMIN ONCOL, V21, P126
[8]  
CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO
[9]  
2-2
[10]   AZU-1:: A candidate breast tumor suppressor and biomarker for tumor progression [J].
Chen, HM ;
Schmeichel, KL ;
Mian, IS ;
Lelièvre, S ;
Petersen, OW ;
Bissell, MJ .
MOLECULAR BIOLOGY OF THE CELL, 2000, 11 (04) :1357-1367